Treatment innovations for metastatic breast cancer: nanoparticle albumin-bound (NAB) technology targeted to tumors.
In spite of recent advances in the treatment of metastatic breast cancer, this disease remains essentially incurable. Anthracyclines and taxanes have been widely demonstrated to be the most active cytotoxic drugs for the treatment of breast cancer. Paclitaxel and docetaxel are both hydrophobic drugs that need to be administered with detergent-like substances as solvents. In contrast, nanoparticle albumin-bound (nab) paclitaxel uses the natural characteristics of albumin to reversibly bind paclitaxel, transport it across endothelial cells and concentrate the active ingredient within the tumor. Several trials have demonstrated that nab-paclitaxel results in superior efficacy, with more complete responses, prolonged time to recurrence and survival, than paclitaxel and docetaxel in MBC. As second-line treatment, the novel formulation has almost doubled overall response rate, increased time to progression and overall survival in comparison with paclitaxel. Due to these results, to date nab-paclitaxel stands out as a promising treatment of metastatic breast cancer.
Hospital Clínico Universitario de Valencia, Valencia, Spain.
Ana
A
Lluch
Hospital Universitario de Donostia, San Sebastian, Spain.
Isabel
I
Alvarez
Hospital Clínic, Barcelona, Spain.
Montserrat
M
Muñoz
Corporació Sanitària Parc Taulí, Barcelona, Spain.
Miguel Ángel
MÁ
Seguí
Hospital del Mar-Parc de Salut Mar, Barcelona, Spain.
Ignasi
I
Tusquets
Centro Integral Oncológico Clara Campal, Madrid, Spain. Electronic address: lestevez@hmhospitales.com.
Laura
L
García-Estévez
D000418:Albumins / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry; D015415:Biomarkers / Q000378:metabolism; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D016503:Drug Delivery Systems; D005260:Female; D006801:Humans; D053758:Nanoparticles / Q000737:chemistry; D036103:Nanotechnology; D009362:Neoplasm Metastasis; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D012106:Research; D043823:Taxoids / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome
C520255:130-nm albumin-bound paclitaxel; D000418:Albumins; D000970:Antineoplastic Agents; D015415:Biomarkers; D043823:Taxoids; D017239:Paclitaxel
Chemotherapy; Metastatic breast cancer; Nab-paclitaxel; SPARC; Taxane